An upcoming phase 1 trial (NCT05353530) has been designed to assess the safety and feasibility of IL-8 receptor-modified CD70 CAR T treatment in CD70+ and MGMT-unmethylated GBM patients. Here, CD70 is linked to glioblastoma.